Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.

@article{Turski2016GenomicallyDT,
  title={Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.},
  author={Michelle L. Turski and Smruti J. Vidwans and Filip Janku and Ignacio Garrido-Laguna and Javier Mu{\~n}oz and Richard B. Schwab and Vivek Subbiah and Jordi Rod{\'o}n and Razelle Kurzrock},
  journal={Molecular cancer therapeutics},
  year={2016},
  volume={15 4},
  pages={533-47}
}
The diagnosis, classification, and management of cancer are traditionally dictated by the site of tumor origin, for example, breast or lung, and by specific histologic subtypes of site-of-origin cancers (e.g., non-small cell versus small cell lung cancer). However, with the advent of sequencing technologies allowing for rapid, low cost, and accurate sequencing of clinical samples, new observations suggest an expanded or different approach to the diagnosis and treatment of cancer-one driven by… CONTINUE READING